Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET
Alzheimer's & Dementia · 2024-02 · 20 (2) · 1225-1238
DOI: 10.1002/alz.13539 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 14.11.2023. Verfasst von Petrice M Cogswell und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, NIA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
INTRODUCTION The timing of plasma biomarker changes is not well understood. The goal of this study was to evaluate the temporal co‐evolution of plasma and positron emission tomography (PET) Alzheimer's disease (AD) biomarkers. METHODS We included 1408 Mayo Clinic Study of Aging and Alzheimer's Disease Research Center participants. An accelerated failure time (AFT) model was fit with amyloid beta (Aβ) PET, tau PET, plasma p‐tau217, p‐tau181, and glial fibrillary acidic protein (GFAP) as endpoints. RESULTS Individual timing of plasma p‐tau progression was strongly associated with Aβ PET and GFAP progression. In the population, GFAP became abnormal first, then Aβ PET, plasma p‐tau, and tau PET temporal meta‐regions of interest when applying cut points based on young, cognitively unimpaired participants. DISCUSSION Plasma p‐tau is a stronger indicator of a temporally linked response to elevated brain Aβ than of tau pathology. While Aβ deposition and a rise in GFAP are upstream events associated with tau phosphorylation, the temporal link between p‐tau and Aβ PET was the strongest. Highlights Plasma p‐tau progression was more strongly associated with Aβ than tau PET. Progression on plasma p‐tau was associated with Aβ PET and GFAP progression. P‐tau181 and p‐tau217 become abnormal after Aβ PET and before tau PET. GFAP became abnormal first, before plasma p‐tau and Aβ PET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Department of Information Technology, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NIH HHS
- NIA NIH HHS
- NINDS NIH HHS
- National Institutes of Health
Zitieren
APA
Cogswell, P. M., Lundt, E. S., Therneau, T. M., Wiste, H. J., Graff-Radford, J., Algeciras-Schimnich, A., Lowe, V. J., Mielke, M. M., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Knopman, D. S., Vemuri, P., Petersen, R. C., & Jack, C. R. (2024). Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET. Alzheimer's & Dementia, 20(2), 1225-1238. https://doi.org/10.1002/alz.13539
Vancouver
Cogswell PM, Lundt ES, Therneau TM, Wiste HJ, Graff-Radford J, Algeciras-Schimnich A, et al. Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET. Alzheimer's & Dementia. 2024;20(2):1225-1238. doi:10.1002/alz.13539
BibTeX
@article{Cogswell2024,
author = {Cogswell, Petrice M and Lundt, Emily S and Therneau, Terry M and Wiste, Heather J and Graff-Radford, Jonathan and Algeciras-Schimnich, Alicia and Lowe, Val J and Mielke, Michelle M and Schwarz, Christopher G and Senjem, Matthew L and Gunter, Jeffrey L and Knopman, David S and Vemuri, Prashanthi and Petersen, Ronald C and Jack, Clifford R},
title = {Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {2},
pages = {1225--1238},
doi = {10.1002/alz.13539}
}
EUVIMED